Virus Or Bacteriophage Patents (Class 424/93.6)
-
Patent number: 8147822Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: GrantFiled: September 18, 2000Date of Patent: April 3, 2012Assignee: Wellstat Biologics CorporationInventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Patent number: 8147823Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: GrantFiled: July 8, 2010Date of Patent: April 3, 2012Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Foundation Inc.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Publication number: 20120076730Abstract: A system for targeted delivery of agents (e.g., molecular probes, diagnostic agents, therapeutic agents, imaging agents, research or analytical compounds, enzymes, peptides, proteins, lipids, lipoproteins, sugars, hormones, vitamins, nucleic acids, viruses, bacteria, and/or cells) including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes a targeting moiety of one of peptides ?3, 2?3, 3?3, A1, B7, B8, B9, B1O, and D6, specific for targeting ICAM-I. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions.Type: ApplicationFiled: June 4, 2010Publication date: March 29, 2012Applicant: UNIVERSITY OF MARYLAND COLLEGE PARKInventors: Silvia Muro Galindo, Ming Meng, Carmen Garnacho Montero
-
Publication number: 20120076771Abstract: The present invention provides compositions and methods for the production of silk fibroin matrices surface-PEGylated on one or more surfaces. Such surface-PEGylated silk fibroin matrices can be used in biomedical applications, such as anti-adhesive and anti-thrombosis materials. Silk matrices may be surface-PEGylated, for example, by a reaction with a functional group-activated PEG. Controlling the degree of PEGylation on surface of silk fibroin matrix can regulate both the degradation rate of the silk matrix, and the differentiated adhesion of cells or differentiated adsorption of proteins on the surface of the silk matrix. The present invention also provides for silk fibroin matrices having one or more surfaces possessing differentiated adhesion properties, which allows for tissue integration on the adherent side and inhibition of tissue adhesion to the opposing tissues or organs.Type: ApplicationFiled: November 17, 2009Publication date: March 29, 2012Applicant: TRUSTEES OF TUFTS COLLEGEInventors: Charu P. Vepari, David L. Kaplan
-
Patent number: 8142796Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.Type: GrantFiled: August 6, 2010Date of Patent: March 27, 2012Assignee: Bavarian Nordic A/SInventors: Anton Mayr, Barbara Mayr
-
Publication number: 20120070427Abstract: The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of ?-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned, enabling the use of these approach for precise control of silk self-assembly, both spatially and temporally. Active agents, including biological materials, viable cells or therapeutic agents, can be encapsulated in the hydrogels formed from the processes, and be used as delivery vehicles. Hence, the present invention provide for methods for silk fibroin gelation that are useful for biotechnological applications such as encapsulation and delivery of active agents, cells, and bioactive molecules.Type: ApplicationFiled: June 1, 2010Publication date: March 22, 2012Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Tuna Yucel
-
Publication number: 20120070414Abstract: The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and/or pathogens and can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, or genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals and plants.Type: ApplicationFiled: November 28, 2011Publication date: March 22, 2012Inventor: Paul Stamets
-
Patent number: 8137947Abstract: The present invention relates to conditionally replicating viruses or pairs of viruses containing a gene switch that is activatable by transient heat or other proteotoxic stress in the presence or absence of a small molecule regulator. The gene switch controls the expression of a gene for a protein required for efficient viral replication and may also control the activity of a passenger gene.Type: GrantFiled: February 1, 2011Date of Patent: March 20, 2012Inventor: Richard Voellmy
-
Patent number: 8137663Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: March 26, 2009Date of Patent: March 20, 2012Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Publication number: 20120063995Abstract: Oncolytic human adenoviral vectors and cells and pharmaceutical compositions including the vectors. Also provided are methods for using the vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, methods of producing an adenoviral vector are provided.Type: ApplicationFiled: February 2, 2010Publication date: March 15, 2012Applicant: ONCOS THERAPEUTICS OYInventors: Otto Hemminki, Gerd Bauerschmitz, Vincenzo Cerullo, Sari Pesonen, Akseli Hemminki
-
Publication number: 20120065071Abstract: The present invention provides a composition including a polymer nanoparticle and at least one agricultural active compound incorporated with the nanoparticle, wherein the nanoparticle are less than 100 nm in diameter, and the polymer includes a polyelectrolyte.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: VIVE NANO, INC.Inventors: Fugang Li, Hung Pham, Darren J. Anderson
-
Patent number: 8133481Abstract: The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus.Type: GrantFiled: February 16, 2010Date of Patent: March 13, 2012Assignee: Canji, Inc.Inventors: Muralidhara Ramachandra, Paul W. Shabram
-
Publication number: 20120052093Abstract: The present invention relates to methods and compositions for preventing and treating uterine disease, and in particular to vaccines and bacteriophage compositions for treating or preventing puerperal metritis, clinical endometritis and/or subclinical endometritis.Type: ApplicationFiled: April 22, 2010Publication date: March 1, 2012Applicant: CORNELL UNIVERSITYInventor: Rodrigo Carvalho Bicalho
-
Publication number: 20120053051Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A1, A2 and A3 are independently selected from the group consisting of CR3 and N; B1 B2 and B3 are independently selected from the group consisting of CR2 and N; Q is a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, —CN, —NO2, —N(R4)R5, —C(W)N(R4)R5, —C(O)OR5 and R8; or —S(O)2N(R21)R22, —S(O)pR25 or —S(O)(?NR28)R29; and R1, R2, R3, R4, R5, R8, R21, R22, R25, R28, R29; p and n are as defined in the disclosure.Type: ApplicationFiled: February 28, 2011Publication date: March 1, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: George Philip Lahm, Kanu Maganbhai Patel, Thomas Francis Pahutski, JR., Benjamin Kenneth Smith
-
Publication number: 20120052048Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: ApplicationFiled: February 5, 2010Publication date: March 1, 2012Applicants: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A., TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SAInventors: Miguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20120052003Abstract: Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of neoplastic cells prior to administration of the cellular composition for therapy. Diagnostic methods for monitoring treatment also are provided.Type: ApplicationFiled: May 15, 2009Publication date: March 1, 2012Inventor: Aladar A. Szalay
-
Patent number: 8124106Abstract: Provided is a method for purifying a virus from a host cell, the method comprising: a) culturing host cells, b) infecting the host cells with a virus, c) treating the cell culture with nuclease, and d) lysing the host cells to provide a lysate comprising the virus. The virus may be recombinant adenovirus. Further provided are methods for purifying a recombinant virus expressing a heterologous protein capable of binding nucleic acid, comprising: a) culturing host cells, b) infecting the host cells with recombinant virus, c) lysing the host cells to provide a lysate comprising the recombinant virus, d) subjecting the recombinant virus to anion exchange chromatography and size exclusion chromatography, wherein the virus-containing mixture is buffer exchanged at least once with a solution comprising at least 2 M NaCl, or another salt providing an equivalent ionic strength.Type: GrantFiled: July 28, 2008Date of Patent: February 28, 2012Assignee: Crucell Holland B.V.Inventors: Miranda Weggeman, Emile J. J. M. van Corven
-
Publication number: 20120045394Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini
-
Patent number: 8119117Abstract: Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.Type: GrantFiled: November 12, 2003Date of Patent: February 21, 2012Assignee: VAXum, LLCInventors: Albert B. Deisseroth, Lixin Zhang
-
Publication number: 20120039956Abstract: The present invention includes compositions and drying methods for preserving sensitive bioactive materials, such as peptides, proteins, hormones, nucleic acids, antibodies, drugs vaccines, yeast, bacteria (probiotic or otherwise), viruses and/or cell suspensions, in storage. The compositions include a carbohydrates component and a glass enhancer component, wherein the carbohydrate component includes a mixture of di-, oligo- and polysaccharides and the glass enhancer includes ions of organic acid and protein hydrolysates. The composition is prepared by dispersing all the solid components in a solution and then snap-frozen to form small beads, strings or droplets. The preferred drying method of the frozen beads, strings or droplets is initiated by a short purging and structure stabilizing step of the frozen particles under a vacuum pressure of less than <2000 mTORR followed by a primary drying step under vacuum pressure of more than >2000 mTORR and at a desired temperature.Type: ApplicationFiled: August 12, 2011Publication date: February 16, 2012Inventors: MOTI HAREL, QIONG TANG
-
Publication number: 20120034164Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated CAR peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.Type: ApplicationFiled: September 1, 2011Publication date: February 9, 2012Inventors: Erkki Ruoslahti, Tero Järvinen, Masanobu Komatsu
-
Publication number: 20120027797Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.Type: ApplicationFiled: October 12, 2011Publication date: February 2, 2012Applicant: Medlmmune, LLCInventor: Vu Truong-Le
-
Publication number: 20120027727Abstract: Targeted gene therapeutic systems are provided for the treatment of cancer, including viral particles. The viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastatic sites. Localized dosing regimens are provided to treat diseases such as cancer.Type: ApplicationFiled: July 15, 2011Publication date: February 2, 2012Applicant: Epeius Biotechnologies CorporationInventors: FREDERICK L. HALL, ERLINDA M. GORDON
-
Patent number: 8105579Abstract: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.Type: GrantFiled: October 4, 2010Date of Patent: January 31, 2012Assignee: BioControl LimitedInventors: James Soothill, Catherine Hawkins, David Harper
-
Patent number: 8105578Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: January 29, 2007Date of Patent: January 31, 2012Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Publication number: 20120020951Abstract: Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.Type: ApplicationFiled: July 15, 2011Publication date: January 26, 2012Inventors: Harold Michael Shepard, Curtis Thompson, Xiaoming Li, Gregory I. Frost
-
Patent number: 8101172Abstract: A Unique Solenopsis invicta virus (SINV 3) has been identified and its genome sequenced. Oligonucleotide primers have been developed using the isolated nucleic acid sequences of the SINV 3. The virus is used as a biocontrol agent for control of fire ants.Type: GrantFiled: February 18, 2009Date of Patent: January 24, 2012Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Steven Valles, Yoshifumi Hashimoto
-
Publication number: 20120009248Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.Type: ApplicationFiled: July 29, 2011Publication date: January 12, 2012Applicant: MedImmune, LLCInventors: Vu Truong-Le, Binh Pham
-
Publication number: 20120010599Abstract: In alternative embodiments, the invention provides articles of manufacture comprising biocompatible nanostructures comprising PolyEther EtherKetone (PEEK) surface-modified (surface-nanopatterned) to exhibit nanostructured surfaces that promote osseointegration and bone-bonding for, e.g., joint (e.g., knee, hip and shoulder) replacements, bone or tooth reconstruction and/or implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as primary or ancillary drug delivery devices. In alternative embodiments, the invention provides biocompatible nanostructures that promote osseointegration and bone-bonding for enhanced cell and bone growth and e.g., for in vitro and in vivo testing, restorative and reconstruction procedures, implants and therapeutics.Type: ApplicationFiled: July 6, 2011Publication date: January 12, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sungho JIN, Garrett SMITH, Chulmin CHOI
-
Publication number: 20110318311Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.Type: ApplicationFiled: March 2, 2010Publication date: December 29, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Tony Reid, Farah Hedjran, Shantanu Kumar
-
Publication number: 20110311490Abstract: The invention provides for a composition comprising a genetically engineered bacteriophage capable of guiding cell growth and polarization via signaling peptides and directionally aligned structures. The invention provides for modified bacteriophage and its uses thereof. The present invention also provides for genetically engineered phage capable of guiding cell growth, migration and/or alignment, providing essential biological effects including proliferation and/or differentiation, which can be performed by expressing specific biological motifs, such as the amino acid sequences RGD, IKVAV, DGEA and HPQ, on their coat proteins, on which functional DNA, proteins and cells can be conjugated and/or fixed thereon.Type: ApplicationFiled: September 27, 2010Publication date: December 22, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Seung-Wuk Lee, Anna Merzlyak
-
Publication number: 20110305634Abstract: The present invention provides compositions and methods for treating disorders associated with epithelial tissues.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Publication number: 20110305768Abstract: This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film strip while maintaining the bioactivity of the contained therapeutic agents during thin film formation and microencapsulation.Type: ApplicationFiled: December 24, 2008Publication date: December 15, 2011Applicant: The Johns Hopkins UniversityInventors: Hai-Quan Mao, Christopher Ku Yu, Vu Linh Truong, Yang Li, Dhanya Rangaraj, Xuesong Jiang, Sagar Ramesh Shah, Derek Sing
-
Publication number: 20110300110Abstract: The novel combinations of enaminocarbonyl compounds and beneficial species comprising, firstly, at least one enaminocarbonyl compound of the formula (I) in which R1 and A have the meanings given in the description, and, secondly, at least one beneficial species (natural enemy).Type: ApplicationFiled: December 3, 2009Publication date: December 8, 2011Applicant: BAYER CROPSCIENCE AGInventors: Heike Hungenberg, Robert Velten, Peter Jeschke, Hans-Jürgen Schnorbach, Wolfram Andersch
-
Publication number: 20110301568Abstract: The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA.Type: ApplicationFiled: April 28, 2011Publication date: December 8, 2011Inventors: Vinod Sharma, Xiaohong Qiu
-
Publication number: 20110293571Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: Oxford BioMedica (UK) Ltd.Inventors: Peter WIDDOWSON, Scott Ralph, Kyriacos A. Mitrophanous
-
Publication number: 20110293516Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.Type: ApplicationFiled: April 11, 2011Publication date: December 1, 2011Inventors: RENATA PASQUALINI, WADIH ARAP, MIKHAIL G. KOLONIN
-
Publication number: 20110293671Abstract: A respirable composition for treatment of a bacterial infection includes one or more active bacteriophages in combination with a pharmaceutically acceptable respirable carrier. The composition includes a carbohydrate carrier, and is prepared as fine powder. In another aspect, bacteriophages are provided in a liquid carrier for administration by nebulization. In one aspect, the bacteriophages have anti-bacterial activity against one or more species or strains of Burkholderia cepacia complex (BCC) bacteria. The invention further relates to the use of a BCC bacteriophage to treat a BCC infection, in particular in an individual suffering from cystic fibrosis.Type: ApplicationFiled: November 26, 2009Publication date: December 1, 2011Inventors: Warren H. Finlay, Jonathan J. Dennis, Helena Orszanska, Kimberley D. Seed, Karlene Heather Lynch
-
Publication number: 20110294668Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.Type: ApplicationFiled: December 7, 2009Publication date: December 1, 2011Applicant: NORTH CAROLINA STATE UNIVERSITYInventors: Christian Melander, John Cavanagh, David F. Ritchie, Steven A. Rogers, Robert W. Huigens, III
-
Publication number: 20110286971Abstract: The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions.Type: ApplicationFiled: June 13, 2011Publication date: November 24, 2011Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Iftach YACOBY, Eliora Z. Ron, Doron Shabat, Marina Shamis, Itai Benhar
-
Publication number: 20110286999Abstract: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.Type: ApplicationFiled: June 28, 2011Publication date: November 24, 2011Inventor: Per Sonne Holm
-
Publication number: 20110286970Abstract: The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease.Type: ApplicationFiled: November 24, 2009Publication date: November 24, 2011Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Beka Solomon, Haim M. Dimant
-
Publication number: 20110286972Abstract: The present invention provides a virus or a viral vector capable of expressing a gene specifically in a cell having replication ability in a hypoxic state such as a cancer stem cell and injuring the cell, and pharmaceutical composition comprising the same. Specifically, the present invention provides a virus or a viral vector which comprises a gene encoding a fusion protein of an ODD and a protein essentially required for viral proliferation, and a pharmaceutical composition comprising the same.Type: ApplicationFiled: January 13, 2009Publication date: November 24, 2011Inventors: Katsuhito Takahashi, Hisako Yamamura, Masahiro Inoue
-
Patent number: 8057806Abstract: A method to prepare viruses lacking ion channel activity is provided.Type: GrantFiled: January 26, 2005Date of Patent: November 15, 2011Assignee: Wisconsin Alumni Research FoundationInventor: Yoshihiro Kawaoka
-
Patent number: 8058251Abstract: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.Type: GrantFiled: October 31, 2007Date of Patent: November 15, 2011Inventor: William F. Kaemmerer
-
Publication number: 20110274661Abstract: The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.Type: ApplicationFiled: August 7, 2009Publication date: November 10, 2011Applicant: The University of ChicagoInventors: Alice P. Poon, Ralph R. Weichselbaum, Bernard Roizman
-
Patent number: 8052967Abstract: Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: September 5, 2007Date of Patent: November 8, 2011Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20110268705Abstract: Methods for inhibiting retinal cell death by altering expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1? in a retinal cell are provided.Type: ApplicationFiled: August 13, 2009Publication date: November 3, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Constance L. Cepko, Bo Chen
-
Patent number: 8043612Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: November 18, 2008Date of Patent: October 25, 2011Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 8043613Abstract: The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.Type: GrantFiled: February 12, 2009Date of Patent: October 25, 2011Assignee: iNtRON Biotechnology, Inc.Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang